文献速递骨质疏松与代谢性骨病

绝经后骨质疏松症地舒单抗治疗时长与末次注射后六个月血清TRAcP5b的关系

The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection.
PubMed 文献 · Osteoporos Int · 2023-10-02

研究纳入59例接受地舒单抗治疗4.0±2.3年(范围1-10年)的绝经后骨质疏松症女性,在末次注射后6.0个月±15天检测血清TRAcP5b、CTX和P1NP。结果显示地舒单抗治疗时长与血清TRAcP5b值或TRAcP5b/CTX比值均无关,而TRAcP5b与CTX显著相关(rs=0.619;p<0.001)。作者认为末次注射后6个月测得的血清TRAcP5b不是识别骨吸收反弹高风险患者的有用早期标志物。

要点

  • 地舒单抗治疗时长与末次注射后6个月血清TRAcP5b值无关。
  • 血清TRAcP5b与CTX显著相关(rs=0.619;p<0.001)。
  • TRAcP5b与P1NP或各骨骼部位BMD均无关。

核心结论

  • 末次地舒单抗注射后6个月测得的血清TRAcP5b不是反映人类破骨细胞随时间累积增加的有用早期标志物,也不能用于识别骨吸收反弹升高风险较高的患者。

研究设计与样本

  • 在59例接受地舒单抗治疗4.0±2.3年(范围1-10年)的绝经后骨质疏松症女性中,于末次注射后6.0个月±15天检测血清TRAcP5b、CTX和P1NP。
  • 其中38例为初治患者(第1组),21例在地舒单抗前接受过其他治疗(第2组)。

主要发现

  • 在整个队列或两个亚组中,地舒单抗治疗时长与血清TRAcP5b值或TRAcP5b/CTX比值均无关。
  • 血清TRAcP5b值与血清CTX值显著相关(rs=0.619;p<0.001)。
  • 血清TRAcP5b值与血清P1NP值或各骨骼部位BMD均无关。

关键数值与推荐

  • 血清TRAcP5b与CTX的相关系数rs=0.619,p<0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: To test the hypothesis that during treatment with denosumab osteomorphs and precursors recycle to higher number of osteoclasts with time, we measured TRAcP5b in serum taken 6 months after the last injection in postmenopausal women treated for 1-10 years. Serum TRAcP5b values were not related to time of exposure to denosumab. PURPOSE: In women with postmenopausal osteoporosis the aetiology of the observed inverse relationship between duration of denosumab (Dmab) therapy and bone loss after its discontinuation is currently unknown. In studies in mice inhibition of RANKL is associated with an increase in osteomorphs and osteoclast precursors that recycle into osteoclasts and may accumulate with time. We hypothesized that longer inhibition of RANKL by Dmab will be followed by the synchronous formation of a larger number of osteoclasts after stopping treatment. To test this hypothesis, we measured serum TRAcP5b, a marker of osteoclast numbers, in postmenopausal women treated with Dmab for different periods of time up to 10 years. METHODS: TRAcP5b, C-terminal telopeptide of type 1 collagen (CTX) and procollagen type 1 N-terminal propeptide (P1NP) were measured at 6.0 months ± 15 days after last Dmab injection in 59 women who had received Dmab for 4.0 ± 2.3 years (range 1-10 years). Of these, 38 were treatment naïve (group 1) and 21 had received other treatments prior Dmab (group 2). RESULTS: Duration of Dmab treatment was not related to serum TRAcP5b values or to TRAcP5b/CTX ratio either in the whole cohort or in each of the two groups separately. In contrast, serum TRAcP5b values were significantly correlated with serum CTX values (rs = 0.619; p < 0.001), but not with serum P1NP values or BMD at all skeletal sites. CONCLUSION: Our observations indicate that serum TRAcP5b, measured at 6 months after a Dmab injection, is not a useful early marker for time-dependent increased accumulation of osteoclasts in humans and for identification of patients at risk for a higher rebound increase in bone resorption.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Makras P, Yavropoulou MP, Polyzos SA, et al. The relationship between length of denosumab treatment for postmenopausal osteoporosis and serum TRAcP5b measured six months after the last injection. Osteoporos Int. 2023. PMID: 37783758. doi:10.1007/s00198-023-06931-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。